Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?
作者信息
O'Reilly Eileen M, Ferrone Cristina
机构信息
Memorial Sloan Kettering Cancer Center, New York, NY.
Weill Cornell Medical College, New York, NY.
出版信息
J Clin Oncol. 2020 Jun 1;38(16):1757-1759. doi: 10.1200/JCO.19.03318. Epub 2020 Mar 2.
Abstract
摘要
相似文献
1
Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?可切除或临界可切除胰腺癌的新辅助治疗或辅助治疗：哪种更优？
J Clin Oncol. 2020 Jun 1;38(16):1757-1759. doi: 10.1200/JCO.19.03318. Epub 2020 Mar 2.
2
Neoadjuvant Chemoradiotherapy for Resectable and Borderline Resectable Pancreatic Cancer.可切除及边界可切除胰腺癌的新辅助放化疗
J Clin Oncol. 2022 Oct 1;40(28):3346. doi: 10.1200/JCO.22.00432. Epub 2022 Jun 23.
3
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.FOLFIRINOX 新辅助治疗联合个体化放化疗治疗边界可切除胰腺腺癌：一项 2 期临床试验。
JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329.
4
Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation.可切除胰腺癌的新辅助治疗与辅助治疗：放疗的作用演变
Semin Radiat Oncol. 2014 Apr;24(2):113-25. doi: 10.1016/j.semradonc.2013.11.002.
5
Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.可切除边缘性胰腺癌及新辅助放化疗的作用
Updates Surg. 2016 Sep;68(3):235-239. doi: 10.1007/s13304-016-0392-x. Epub 2016 Sep 15.
6
Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.新辅助治疗胰腺癌：定义与获益。
Int J Mol Sci. 2017 Jul 26;18(8):1622. doi: 10.3390/ijms18081622.
7
[Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].[原发性可切除及临界可切除胰腺癌的新辅助治疗]
Chirurg. 2020 May;91(5):391-395. doi: 10.1007/s00104-019-01093-7.
8
New developments in the management of borderline resectable pancreatic cancers.可切除边缘性胰腺癌治疗的新进展
JOP. 2013 Jul 10;14(4):334-6. doi: 10.6092/1590-8577/1681.
9
Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.可切除、交界可切除和局部进展期胰腺癌新辅助治疗的意见和应用：国际调查和病例简述研究。
BMC Cancer. 2019 Jul 9;19(1):675. doi: 10.1186/s12885-019-5889-5.
10
[Borderline resectable pancreatic cancer - a definition and effective treatment strategy].[可切除边缘性胰腺癌——定义及有效治疗策略]
Gan To Kagaku Ryoho. 2012 Mar;39(3):337-41.
引用本文的文献
1
The immune-related prognostic gene AIM2 promotes pancreatic cancer progression via inflammasome.免疫相关预后基因AIM2通过炎性小体促进胰腺癌进展。
Sci Rep. 2025 Aug 13;15(1):29733. doi: 10.1038/s41598-025-12651-x.
2
Phospholipid-Rich DC-Vesicles with Preserved Immune Fingerprints: A Stable and Scalable Platform for Precision Immunotherapy.具有保留免疫指纹的富含磷脂的树突状细胞囊泡：用于精准免疫治疗的稳定且可扩展的平台。
Biomedicines. 2025 May 26;13(6):1299. doi: 10.3390/biomedicines13061299.
3
Interview with Prof. Dr. Jeffrey Drebin, President of the 2024 President Elect of the American Surgical Association.对美国外科协会2024年当选主席杰弗里·德雷宾教授的采访。
Ann Gastroenterol Surg. 2024 Nov 22;9(1):24-31. doi: 10.1002/ags3.12882. eCollection 2025 Jan.
4
Comparative Efficacy of 21 Treatment Strategies for Resectable Pancreatic Cancer: A Network Meta-Analysis.可切除胰腺癌21种治疗策略的比较疗效：一项网状Meta分析
Cancers (Basel). 2024 Sep 20;16(18):3203. doi: 10.3390/cancers16183203.
5
Multimodal Approaches to Patient Selection for Pancreas Cancer Surgery.多模态方法在胰腺癌手术患者选择中的应用。
Curr Oncol. 2024 Apr 15;31(4):2260-2273. doi: 10.3390/curroncol31040167.
6
Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.新辅助治疗与手术优先治疗可切除或交界可切除胰腺癌的比较：一项随机对照试验的系统评价和网络荟萃分析。
PLoS One. 2024 Mar 7;19(3):e0295983. doi: 10.1371/journal.pone.0295983. eCollection 2024.
7
Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.术前化疗联合 nab-紫杉醇和吉西他滨治疗边界可切除或淋巴结阳性胰腺导管腺癌的 2 期研究。
Cancer Med. 2023 Jun;12(12):12986-12995. doi: 10.1002/cam4.5971. Epub 2023 May 3.
8
Survival After Minimally Invasive vs Open Surgery for Pancreatic Adenocarcinoma.胰腺腺癌微创手术与开放手术的生存比较。
JAMA Netw Open. 2022 Dec 1;5(12):e2248147. doi: 10.1001/jamanetworkopen.2022.48147.
9
Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer.围手术期血清评分系统可预测可切除胰腺癌的早期复发和不良预后。
Front Oncol. 2022 Feb 21;12:841819. doi: 10.3389/fonc.2022.841819. eCollection 2022.
10
Roles and Clinical Significances of ATF6, EMC6, and APAF1 in Prognosis of Pancreatic Cancer.ATF6、EMC6和APAF1在胰腺癌预后中的作用及临床意义
Front Genet. 2022 Feb 11;12:730847. doi: 10.3389/fgene.2021.730847. eCollection 2021.
本文引用的文献
1
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.可切除及临界可切除胰腺癌的术前放化疗与直接手术对比：荷兰随机III期PREOPANC试验结果
J Clin Oncol. 2020 Jun 1;38(16):1763-1773. doi: 10.1200/JCO.19.02274. Epub 2020 Feb 27.
2
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.新辅助 FOLFIRINOX 方案在边界可切除胰腺癌患者中的应用：系统评价和患者水平的荟萃分析。
J Natl Cancer Inst. 2019 Aug 1;111(8):782-794. doi: 10.1093/jnci/djz073.
3
Pancreatic Adenocarcinoma, Version 1.2019.胰腺导管腺癌临床实践指南（2019 年版）
J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210. doi: 10.6004/jnccn.2019.0014.
4
Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis.化疗与放化疗作为可切除胰腺导管腺癌术前治疗的比较：倾向评分调整分析
Pancreas. 2019 Feb;48(2):216-222. doi: 10.1097/MPA.0000000000001231.
5
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).吉西他滨与S-1新辅助化疗对比直接手术治疗可切除胰腺癌的随机II/III期试验（Prep-02/JSAP05）
Jpn J Clin Oncol. 2019 Feb 1;49(2):190-194. doi: 10.1093/jjco/hyy190.
6
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.FOLFIRINOX 或吉西他滨作为胰腺癌的辅助治疗。
N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.
7
A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.局部胰腺导管腺癌的分子谱分析新辅助治疗的 II 期临床试验。
Ann Surg. 2018 Oct;268(4):610-619. doi: 10.1097/SLA.0000000000002957.
8
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.FOLFIRINOX 新辅助治疗联合个体化放化疗治疗边界可切除胰腺腺癌：一项 2 期临床试验。
JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329.
9
Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.新辅助治疗胰腺腺癌：5520 例患者的系统评价和荟萃分析。
World J Surg Oncol. 2017 Oct 10;15(1):183. doi: 10.1186/s12957-017-1240-2.
10
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.比较吉西他滨和卡培他滨辅助治疗与吉西他滨单药治疗可切除胰腺癌患者的效果（ESPAC-4）：一项多中心、开放标签、随机、3 期临床试验。
Lancet. 2017 Mar 11;389(10073):1011-1024. doi: 10.1016/S0140-6736(16)32409-6. Epub 2017 Jan 25.
Zotero 插件